Oncology JP Morgan 2023 – Adi Hoess pharmaphorum editor-in-chief Jonah Comstock joins Adi Hoess, CEO of Affimed, at the Zeppelin Hotel in San Francisco, to learn about
News AACR: Affimed builds case for natural killer cell therapy Affimed says new data from a phase 1/2 trial of its natural killer (NK) cell engager therapy AFM13 provide further evidence of its efficacy in treating CD30+ Hodgkin and non-Hodgkin lymphom
News Affimed and Roche ink $5bn plus cancer immunotherapy deal Deal is based on natural killer cell therapeutics
Digital Asking the right questions around AI, with Brian Alexander, ... At BIO 2025, editor-in-chief Jonah Comstock spoke with Brian Alexander, CEO of Valo Health, about how he’s seeing the AI conversation evolve.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face